In 2022, the global Fabry disease market is expected to be worth $1.9 billion. The market is expected to grow at an 8% CAGR between 2022 and 2032, reaching a market valuation of US$ 4.10 billion by 2032. The market's high expansion in the coming years can be attributed to ongoing advancements in Fabry disease treatment methods.
Anderson-Fabry disease and alpha-galactosidase A deficiency are other names for Fabry disease. It is a rare hereditary lipid metabolism condition caused by insufficient activity of the alpha-galactosidase A (a-Gal A) enzyme. The enzyme deficit is caused by changes in the genes that instruct the cells to produce alpha-galactosidase A (a-Gal A).
Fabry disease has been linked to a number of systemic signs and consequences, one of which is metabolic abnormalities. In Fabry disease, sphingolipid metabolism is reduced, resulting in multiple organ failure and death. Because to a lack of the alpha galactosidase A enzyme, glycolipid termed Gb3 accumulates in blood vessels and other organs, causing blockages or clots that cause the system to fail.
The market for Fabry disease is expected to grow throughout the forecast period because to the ongoing rise in the incidence rate of this genetic disorder. In general, treatment techniques such as enzyme replacement therapy (ERT) and chaperone, which were designed to ameliorate clinical symptoms in Fabry disease patients, are utilised to treat them. As a result, an increasing number of patients and increased utilisation of these treatments are expected to aid market expansion over the forecast period. Furthermore, the rising prevalence of late-onset and type 1 classic Fabry disease, particularly among men, is fueling market expansion.
Fabry Disease Market: Key Players
The major players operating in this market and involved in development of new medications include Sanofi-Aventis LLC, iBio, Inc., GlaxoSmithKline plc, Genzyme Corporation, and Neuraltus Pharmaceuticals, Inc. Some of the existing key players in the global fabry disease market are Novartis Pharmaceuticals, Merc & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Amgen Inc., Teva pharmaceutical Industries Ltd., Pfizer Inc., Takeda Pharmaceutical Co. Ltd
Read More@ https://www.futuremarketinsights.com/reports/fabry-disease-market
Fabry Disease Market: Segmentation
The global fabry disease market has been classified on the basis of treatment, end use and geography.
Based on treatment, the global fabry disease market is divided into following:
- Enzyme replacement therapy
- Gene therapy
- Pharmaceutical formulations containing agalsidase alpha
- Analgesics
- Anticonvulsants
- NSAIDs
Based on end user type, the global fabry disease market is divided into following:
- Hospitals
- Clinics
Fabry Disease Market Research Report: by type (type-1 and type-2), diagnosis & treatment (diagnosis (blood test, urine test, imaging, others, treatment (Enzyme Replacement and Gene Therapy, Anticonvulsants, others))), by end user - Global Forecast Till 2027Market Highlights:The Global Fabry Disease Market is expected to grow at a CAGR of 6.8% during the forecast period.
Technological advancements, strong pipeline, advancements in healthcare facilities, and favorable funding policies are expected to drive the market growth over the forecast period.
Owing to the increasing awareness about Fabry disease, new and existing market players are coming up with better treatment approaches.
For instance, in 2018, 2018, Amicus Therapeutics launched Galafold capsules 123mg for the treatment of patients aged 16 years and older with a confirmed diagnosis of Fabry disease and who have an amenable mutation.However, diverse range of symptoms, and related complications can restrain the market growth over the assessment period.Regional Analysis:Geographically, the Americas is expected to dominate the global market owing to the increasing technological advancements and rising research and development activities.
So, for the advanced treatment of these patients SmartPill testing procedure is developed to gain additional understanding of Fabry disease manifestation via motility abnormalities in order to improve symptom targeted therapy.
This device is currently under clinical trial and the sponsor of this study is Massachusetts General Hospital.Request Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/7064Europe is expected to hold the second largest market share.
